Marcu Constantin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marcu Constantin has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Vornicu
Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iași, Romania
1 shared publication - Alina Monica Miftode
Department of General and Inorganic Chemistry, Faculty of Pharmacy, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
1 shared publication - Alina Stefanache
Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iași, Romania
1 shared publication - Cristian Gutu
Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galati, 47 Domnească Street, 800008 Galati, Romania
1 shared publication - Ionut Iulian Lungu
Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
1 shared publication - Iulia Olaru
Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galati, 47 Domnească Street, 800008 Galati, Romania
1 shared publication
Latest Publications
- Open Access
- 19 February 2025
- Published by MDPI AG in Inorganics
- Vol. 13 (2) , 64
Noble Metal Complexes in Cancer Therapy: Unlocking Redox Potential for Next-Gen Treatments
(1) Context: Cancer is still a major problem worldwide, and traditional therapies like radiation and chemotherapy often fail to alleviate symptoms because of side effects, systemic toxicity, and mechanisms of resistance. Beneficial anticancer effects that spare healthy tissues are made possible by the distinctive redox characteristics of noble metal complexes, especially those containing palladium, gold, silver, and platinum. (2) Methods: The redox processes, molecular targets, and therapeutic uses of noble metal complexes in cancer have been the subject of much study over the last 20 years; novel approaches to ligand design, functionalization of nanoparticles, and tumor-specific drug delivery systems are highlighted. (3) Results: Recent developments include Pt(IV) prodrugs and terpyridine-modified Pt complexes for enhanced selectivity and decreased toxicity; platinum complexes, like cisplatin, trigger reactive oxygen species (ROS) production and DNA damage. Functionalized gold nanoparticles (AuNPs) improve targeted delivery and theranostic capabilities, while gold complexes, particularly Au(I) and Au(III), inhibit redox-sensitive processes such as thioredoxin reductase (TrxR). (4) Conclusions: Ag(I)-based compounds and nanoparticles (AgNPs) induce DNA damage and mitochondrial dysfunction by taking advantage of oxidative stress. As redox-based anticancer medicines, noble metal complexes have the ability to transform by taking advantage of certain biochemical features to treat cancer more effectively and selectively.
- 19 February 2025
- Published by MDPI AG in Inorganics
- Vol. 13 (2) , 64
Open AccessNoble Metal Complexes in Cancer Therapy: Unlocking Redox Potential for Next-Gen Treatments
(1) Context: Cancer is still a major problem worldwide, and traditional therapies like radiation and chemotherapy often fail to alleviate symptoms because of side effects, systemic toxicity, and mechanisms of resistance. Beneficial anticancer effects that spare healthy tissues are made possible by the distinctive redox characteristics of noble metal complexes, especially those containing palladium, gold, silver, and platinum. (2) Methods: The redox processes, molecular targets, and therapeutic uses of noble metal complexes in cancer have been the subject of much study over the last 20 years; novel approaches to ligand design, functionalization of nanoparticles, and tumor-specific drug delivery systems are highlighted. (3) Results: Recent developments include Pt(IV) prodrugs and terpyridine-modified Pt complexes for enhanced selectivity and decreased toxicity; platinum complexes, like cisplatin, trigger reactive oxygen species (ROS) production and DNA damage. Functionalized gold nanoparticles (AuNPs) improve targeted delivery and theranostic capabilities, while gold complexes, particularly Au(I) and Au(III), inhibit redox-sensitive processes such as thioredoxin reductase (TrxR). (4) Conclusions: Ag(I)-based compounds and nanoparticles (AgNPs) induce DNA damage and mitochondrial dysfunction by taking advantage of oxidative stress. As redox-based anticancer medicines, noble metal complexes have the ability to transform by taking advantage of certain biochemical features to treat cancer more effectively and selectively.